Vaccine Information: Flulaval Quadrivalent 2021/2022 (Page 4 of 4)

15 REFERENCES

1.
Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103:133-138.
2.
Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg Camb. 1972;70:767-777.

16 HOW SUPPLIED/STORAGE AND HANDLING

FLULAVAL QUADRIVALENT is available in 0.5-mL single-dose, disposable, prefilled TIP-LOK syringes (packaged without needles).

NDC 19515-818-41 Syringe in Package of 10: NDC 19515-818-52

Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen. Store in the original package to protect from light.

17 PATIENT COUNSELING INFORMATION

Provide the following information to the vaccine recipient or guardian:

Inform of the potential benefits and risks of immunization with FLULAVAL QUADRIVALENT.
Educate regarding potential side effects, emphasizing that (1) FLULAVAL QUADRIVALENT contains non-infectious killed viruses and cannot cause influenza, and (2) FLULAVAL QUADRIVALENT is intended to provide protection against illness due to influenza viruses only, and cannot provide protection against all respiratory illness.
Encourage women exposed to FLULAVAL QUADRIVALENT during pregnancy to enroll in the pregnancy registry [see Use in Specific Populations (8.1)].
Give the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 prior to each immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).
Instruct that annual revaccination is recommended.

FLUARIX, FLULAVAL, HAVRIX, and TIP-LOK are trademarks owned by or licensed to the GSK group of companies. The other brand listed is a trademark owned by or licensed to the respective owner and is not owned by or licensed to the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.

Manufactured by ID Biomedical Corporation of Quebec

Quebec City, QC, Canada, U.S. License 1739

Distributed by GlaxoSmithKline

Research Triangle Park, NC 27709

©2021 GSK group of companies or its licensor.

FVQ:11PI

PRINICIPAL DISPLAY PANEL

NDC 19515-818-52

FLULAVAL QUADRIVALENT

Influenza Vaccine

2021/2022 Formula

Rx only

For 6 Months of Age and Older

10 Disposable Single-Dose Prefilled TIP-LOK Syringes each containing one 0.5 mL dose

TIP-LOK Syringes are compatible with LUER-LOK needles

NEEDLES NOT INCLUDED

Gsk

Flulaval Quadrivalent

Made in Canada

©2021 GSK group of companies or its licensor.

Rev. 4/21

506500

Flulaval Quadrivalent 2021-2022 10 count syringe carton
(click image for full-size original)
FLULAVAL QUADRIVALENT 2021/2022 influenza virus vaccine suspension
Product Information
Product Type VACCINE Item Code (Source) NDC:19515-818
Route of Administration INTRAMUSCULAR DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) (INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED)) INFLUENZA A VIRUS A/VICTORIA/2570/2019 IVR-215 (H1N1) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug in 0.5 mL
INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED) (INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED)) INFLUENZA A VIRUS A/TASMANIA/503/2020 IVR-221 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug in 0.5 mL
INFLUENZA B VIRUS B/WASHINGTON/02/2019 ANTIGEN (UV, FORMALDEHYDE INACTIVATED) (INFLUENZA B VIRUS B/WASHINGTON/02/2019 HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED)) INFLUENZA B VIRUS B/WASHINGTON/02/2019 HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug in 0.5 mL
INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN (UV, FORMALDEHYDE INACTIVATED) (INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED)) INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED) 15 ug in 0.5 mL
Inactive Ingredients
Ingredient Name Strength
SODIUM CHLORIDE
SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
POTASSIUM PHOSPHATE, MONOBASIC
POTASSIUM CHLORIDE
.ALPHA.-TOCOPHEROL SUCCINATE, D-
POLYSORBATE 80
WATER
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:19515-818-52 10 SYRINGE in 1 CARTON contains a SYRINGE (19515-818-41)
1 NDC:19515-818-41 0.5 mL in 1 SYRINGE This package is contained within the CARTON (19515-818-52)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
BLA BLA125163 07/02/2021 06/30/2022
Labeler — ID Biomedical Corporation of Quebec (243368284)

Revised: 07/2021 ID Biomedical Corporation of Quebec

Page 4 of 4 1 2 3 4

VxLabels.com provides trustworthy package insert and label information about marketed drugs and vaccines as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VxLabels.com. Every individual vaccine label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Vaccine Sections

Vaccine Information by RSS

As the leading independent provider of trustworthy vaccine information, our database comes directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. VxLabels.com provides the full vaccine subset of the FDA's repository. Vaccine information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2021. All Rights Reserved.